PIK3CA-Related Overgrowth Spectrum Treatments
Find PIK3CA-Related Overgrowth Spectrum Treatments
Medications for PIK3CA-Related Overgrowth Spectrum
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in PIK3CA-Related Overgrowth Spectrum.
Found 1 Approved Drug for PIK3CA-Related Overgrowth Spectrum
Alpelisib
Brand Names
Vijoice, Piqray
Alpelisib
Brand Names
Vijoice, Piqray
Form: Tablet, Kit, Granule
Method of administration: Oral
FDA approval date: May 24, 2019
PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances